Skip to main content
Erschienen in: Medical Oncology 3/2007

01.09.2007 | Original Paper

Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia

verfasst von: M. L. V. Jacober, R. L. Mamoni, C. S. P. Lima, B. L. dos Anjos, H. Z. W. Grotto

Erschienen in: Medical Oncology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Hepcidin has been proposed as an important factor in the pathogenesis of the anaemia of chronic disease (ACD). The aim of this study was to assess the relationship between anaemia and inflammatory activity in patients with solid tumours. Patients were classified as having iron deficiency anaemia (IDA) (hypoferremia and hypoferretinemia), ACD (hypoferremia, normal or increased serum ferritin) and anaemia related to cancer (ARC) (no abnormalities in iron status). Serum pro-hepcidin, IL-6, C-reactive protein (CRP) and iron status parameters were measured using commercial kits. CRP and IL-6 levels were significantly higher in patients with ACD when compared to IDA, ARC and non anaemic patients (P < 0.005). Serum pro-hepcidin levels were not different among all studied groups (P = 0.138). A negative correlation was observed between haemoglobin and serum ferritin, CRP and IL-6 levels only in group of ACD. Serum pro-hepcidin concentrations were not correlated with degree of anaemia or iron metabolism parameters. According to our results the inflammatory activity represented by high levels of IL-6 and CRP are involved in the pathogenesis of ACD, probably due to the action of inflammation on iron metabolism, but not in ARC. It was not possible to demonstrate a significant effect of pro-hepcidin on the anaemia in cancer patients.
Literatur
1.
Zurück zum Zitat Harrison L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28:54–9.PubMedCrossRef Harrison L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28:54–9.PubMedCrossRef
2.
Zurück zum Zitat Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25:2–6.PubMed Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25:2–6.PubMed
3.
Zurück zum Zitat Weiss G, Goodnough LT. Medical progress: anemia of chronic disease. N Engl J Med 2005;352:1011–23.PubMedCrossRef Weiss G, Goodnough LT. Medical progress: anemia of chronic disease. N Engl J Med 2005;352:1011–23.PubMedCrossRef
4.
Zurück zum Zitat Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haematol 2005;27:1–13.PubMedCrossRef Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haematol 2005;27:1–13.PubMedCrossRef
5.
Zurück zum Zitat Nemeth E, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone Hepcidin. J Clin Invest 2004;113:1271–6.PubMedCrossRef Nemeth E, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone Hepcidin. J Clin Invest 2004;113:1271–6.PubMedCrossRef
6.
Zurück zum Zitat Macciò A, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005;106:362–7.PubMedCrossRef Macciò A, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005;106:362–7.PubMedCrossRef
7.
Zurück zum Zitat Ganz T. Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171–82.PubMedCrossRef Ganz T. Hepcidin—a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2005;18:171–82.PubMedCrossRef
9.
Zurück zum Zitat Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2701–4.CrossRef Dallalio G, Law E, Means RT Jr. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 2006;107:2701–4.CrossRef
10.
Zurück zum Zitat Hinzmann R. Iron metabolism, iron deficiency and anaemia. Sysmex J Internat 2003;13:65–74. Hinzmann R. Iron metabolism, iron deficiency and anaemia. Sysmex J Internat 2003;13:65–74.
11.
Zurück zum Zitat Theurl I, et al. Dysregulated monocytes iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 2006;107:4142–8.PubMedCrossRef Theurl I, et al. Dysregulated monocytes iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood 2006;107:4142–8.PubMedCrossRef
12.
Zurück zum Zitat Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14–23.PubMedCrossRef Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005;11:14–23.PubMedCrossRef
13.
Zurück zum Zitat Sweeney PJ, et al. Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomised, open-labelled, phase II trials. Br J Cancer 1998;77:1996–2002.PubMed Sweeney PJ, et al. Effect of subcutaneous recombinant human erythropoetin in cancer patients receiving radiotherapy: final report of a randomised, open-labelled, phase II trials. Br J Cancer 1998;77:1996–2002.PubMed
14.
Zurück zum Zitat Bokemeyer C, Foubert J. Anemia impact and management: focus on patients needs and the use of erythropoietic agents. Semin Oncol 2004;31:4–11.PubMedCrossRef Bokemeyer C, Foubert J. Anemia impact and management: focus on patients needs and the use of erythropoietic agents. Semin Oncol 2004;31:4–11.PubMedCrossRef
15.
Zurück zum Zitat Noronha JFA, Grotto HZW. Measurement of reticulocyte and red blood cell indices in patients with iron deficiency and β-thalassemia minor. Clin Chem Lab Med 2005;43:195–7.PubMedCrossRef Noronha JFA, Grotto HZW. Measurement of reticulocyte and red blood cell indices in patients with iron deficiency and β-thalassemia minor. Clin Chem Lab Med 2005;43:195–7.PubMedCrossRef
16.
Zurück zum Zitat Fuchs D, Zangerle R, Denz H, Wachter H. Inhibitory cytokines in patients with anemia of chronic disorders. Ann NY Acad Sci 1994;718:344–6.PubMedCrossRef Fuchs D, Zangerle R, Denz H, Wachter H. Inhibitory cytokines in patients with anemia of chronic disorders. Ann NY Acad Sci 1994;718:344–6.PubMedCrossRef
17.
Zurück zum Zitat Jelkmann W. Proinflammatory cytokins lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555–559.PubMedCrossRef Jelkmann W. Proinflammatory cytokins lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555–559.PubMedCrossRef
18.
19.
Zurück zum Zitat Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–3.PubMedCrossRef Nemeth E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090–3.PubMedCrossRef
20.
Zurück zum Zitat Nemeth E, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461–3.PubMedCrossRef Nemeth E, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461–3.PubMedCrossRef
21.
Zurück zum Zitat Détivaud L, et al. Hepcidin levels in human are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746–8.PubMedCrossRef Détivaud L, et al. Hepcidin levels in human are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746–8.PubMedCrossRef
22.
Zurück zum Zitat Kulaksiz H, et al. Pro-hepcidin: expression and cell specific localization in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735–43.PubMedCrossRef Kulaksiz H, et al. Pro-hepcidin: expression and cell specific localization in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735–43.PubMedCrossRef
23.
Zurück zum Zitat Dallalio G, Fleury T, Means RT Jr. Serum Hepcidin in clinical specimens. Br J Haematol 2003;122:996–1000.PubMedCrossRef Dallalio G, Fleury T, Means RT Jr. Serum Hepcidin in clinical specimens. Br J Haematol 2003;122:996–1000.PubMedCrossRef
24.
Zurück zum Zitat Brookes MJ, Sharma NK, Tselepis C, Iqbal TH. Serum pro-hepcidin: measuring active Hepcidin or a non-functional precursor? Gut 2005;54:169–70.PubMedCrossRef Brookes MJ, Sharma NK, Tselepis C, Iqbal TH. Serum pro-hepcidin: measuring active Hepcidin or a non-functional precursor? Gut 2005;54:169–70.PubMedCrossRef
Metadaten
Titel
Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia
verfasst von
M. L. V. Jacober
R. L. Mamoni
C. S. P. Lima
B. L. dos Anjos
H. Z. W. Grotto
Publikationsdatum
01.09.2007
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 3/2007
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-0009-9

Weitere Artikel der Ausgabe 3/2007

Medical Oncology 3/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.